New Startup Marrow Therapeutics Launches with $173 Million to Tackle Sickle Cell Disease
Biotech entrepreneur Romesh Subramanian has launched Marrow Therapeutics, securing $173 million in funding to develop a potential alternative to gene therapy for sickle cell disease.
🔬ResearchPhoto: statnews.com
Key points
- Marrow Therapeutics launched with $173 million in Series A and B funding.
- Backers include Scion Life Sciences, venBio, and OrbiMed.
- The startup aims to develop a treatment as effective as gene therapy without its drawbacks.
A newly formed biotechnology enterprise, Marrow Therapeutics, has emerged with $173 million in combined Series A and B financing to pursue alternative treatments for sickle cell disease. The funding round was supported by prominent backers including Scion Life Sciences, venBio, and OrbiMed, according to an announcement made on Tuesday by founder and biotech entrepreneur Romesh Subramanian.
For years, investigators and financial backers have sought therapeutic approaches that match the efficacy of complex gene therapies while avoiding their significant procedural drawbacks. Subramanian expressed optimism regarding the new venture's approach, stating that the therapy is anticipated to offer comparable effectiveness for patients, though clinical proof remains to be established.
What to know: While the financial backing is substantial, the initiative is in its early stages, and clinical data confirming its efficacy in humans has not yet been detailed. Readers considering any medical treatments or clinical trials should consult a qualified physician for personalized guidance.
Source statnews.com — statnews.com/2026/11/17/new-startup-developing-novel-sickle-cell-an… ↗
Read next
🏥Public HealthPreventive Services Task Force Resumes Meetings Under New Leadership
The U.S. Preventive Services Task Force is set to reconvene this week for the first time in over a year following a significant membership overhaul by Health Secretary Ro…
❤️Conditions & CareBlood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma
Researchers have identified a specific RNA signature in blood plasma that may help predict how well lymphoma patients respond to CAR T-cell therapy.
🧠AI AnalysisUltraprocessed Diets May Impact Brain Reward Systems in Younger Adults
A Virginia Tech study suggests that individuals aged 18 to 21 may experience changes in brain reward processing after consuming ultraprocessed foods, a response not obser…
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
❤️Conditions & CareMigraine and Smoking Linked to Increased Early Stroke Risk in Women
A large-scale study suggests that people who have given birth and experience migraines while also smoking face a significantly higher risk of stroke before age 60.
🏃FitnessExpert Advice on Hydration Gear Sparks Debate Among Recreational Runners
Olympic medalist Josh Kerr recently suggested that runners may not require hydration packs for distances under 12 miles, igniting a broader conversation about gear necess…